These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. New promises for schizophrenia therapy. Sridhar N Drug Discov Today; 2002 Feb; 7(4):215-6. PubMed ID: 11839513 [No Abstract] [Full Text] [Related]
7. What is an atypical antipsychotic? Reynolds GP J Psychopharmacol; 1997; 11(3):195-9. PubMed ID: 9305410 [TBL] [Abstract][Full Text] [Related]
8. [Theory in antipsychotic drug therapy for schizophrenia]. Tomioka S; Ishigooka J Seishin Shinkeigaku Zasshi; 2006; 108(6):614-8. PubMed ID: 16910539 [TBL] [Abstract][Full Text] [Related]
9. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients. Düring S; Glenthøj BY; Oranje B Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696 [TBL] [Abstract][Full Text] [Related]
10. British Association for Psychopharmacology--2008 Summer Meeting. Jenkins TA IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070 [No Abstract] [Full Text] [Related]
11. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302 [TBL] [Abstract][Full Text] [Related]
12. Investigational dopamine antagonists for the treatment of schizophrenia. Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355 [TBL] [Abstract][Full Text] [Related]
13. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282 [TBL] [Abstract][Full Text] [Related]
14. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply. Lako IM; Liemburg EJ; Van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K J Clin Psychopharmacol; 2014 Aug; 34(4):532-3. PubMed ID: 24949704 [No Abstract] [Full Text] [Related]
15. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Tsuboi T; Suzuki T; Bies RR; Remington G; Pollock BG; Mimura M; Uchida H Schizophr Res; 2015 May; 164(1-3):149-54. PubMed ID: 25864950 [TBL] [Abstract][Full Text] [Related]
16. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. Lee J; Takeuchi H; Remington G J Clin Psychopharmacol; 2014 Aug; 34(4):530-2. PubMed ID: 24875070 [No Abstract] [Full Text] [Related]
17. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice. Nakata Y; Kanahara N; Iyo M J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317 [TBL] [Abstract][Full Text] [Related]
18. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489 [TBL] [Abstract][Full Text] [Related]